(2S,3S,4R)-2-Aminooctadecane-1,3,4-triol, 95.0%, 1g

1-butyl-5-oxopyrrolidine-3-carboxylic acid, 95.0%, 1g

3-(3-Fluoro-phenyl)-3-oxo-propionic acid ethylester, 97.0%, 5g

1-[(1,3-Benzothiazol-2-ylsulfanyl)methyl]-1H-1,2,3-benzotriazole, 90.0%, 1g

2-Acetyl-3-methylquinoxaline 1,4-dioxide, 95+%, 100g

2H-Imidazo[4,5-c]quinolin-2-one, 7-(3,5-dimethyl-4-isoxazolyl)-1,3-dihydro-8-methoxy-1-[(1R)-1-(2-pyridinyl)ethyl]-, 98%, 1mg

2-Chloro-4,6-bis(naphthalene-2-yl)-1,3,5-triazine, 97%, 5g

[(2E)-3-(4-methoxyphenyl)prop-2-en-1-yl](prop-2-en-1-yl)amine, 95.0%, 10g

6-Isopropylpyridin-2-amine, 95.0%, 1g

Glass syringe Dosys with Luer connection (glass), 1 ml, 3 pieces

Bromoethane, min 99.5%, for synthesis, 2.5 L, glass packaging

3-[1'-ethyl-5-(trifluoromethyl)-1H,1'H-3,4'-bipyrazol-1-yl]propan-1-amine, 1g

2-(5-Methoxy-2-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, 98%, 1g